The State
Institute for Drug Control (SÚKL) has initiated its first ex officio
proceeding to re-evaluate whether a Highly Innovative Medicinal Product
(VILP) continues to meet the required criteria following the entry of a new
comparator into the reimbursement system.
Under the Public
Health Insurance Act, if, during the validity of a decision granting...
Are you interested in reading regular commentaries on decisions by Pharmeca a.s.? Feel free to contact us.
At Pharmeca, we help you navigate the complex landscape of pharmaceutical and medical device information. We also offer flexible services that can be tailored to your needs at any time.
Our market position and experience allow us to support you whenever you need expert guidance.
Our knowledge, your opportunity.
